Filter posts

BIO Communications Responds to Misleading Op-Ed about Medicaid Drug Costs

This week, Dr. Peter Bach of Memorial Sloan-Kettering Cancer Center authored an op-ed about the …

ICER Comes Under Renewed Scrutiny

As we enter a new and exciting era of medicine, there is an important question …

Value Assessment Tools that take “Precision” out of “Precision Medicine” are Harmful to Pati...

The conversation about health care costs is front and center in Washington, and new data …

Five Oncologists Weigh in on Value Frameworks

Value Frameworks, which attempt to quantify the value of a medicine, have been a hot …

Despite Latest Report, ICER Still Limits Patient Input and Maintains Strong Ties To Insurers

After months of criticism, including some from BIO, the Institute for Clinical and Economic Review …

ICER’s Methodology Needs to Take Into Account Key Stakeholder Voices

Last week, the Institute for Clinical and Economic Review (ICER) released the scoping document for …

ICER's Flawed Methodology Could Lead To Healthcare Rationing

In a column published in USA Today recently, Jeff Stier, a Senior Fellow at the …